Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma

Blood

Volumn 106, Issue 10, 2005, Pages 3538-3545

  Jalili, Ali ^b   Ozaki, Shuji ^a   Hara, Tomoko ^b   Shibata, Hironobu ^b   Hashimoto, Toshihiro ^b   Abe, Masahiro ^b   Nishioka, Yasuhiko ^b   Matsumoto, Toshio ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLPROLYLGLUTAMINYLLEUCYLLEUCYLISOLEUCYLVALYLLEUCYLLEUCINE; ANTIGEN; ARGINYLLEUCYLARGINYLARGINYLGLUTAMYLASPARAGINYLGLUTAMINYLVALYLLEUCINE; CD8 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HM1.24 ANTIGEN; ISOLEUCYLMETHIONYLPROLYLLYSYLALANYLGLYCYLLEUCYLLEUCYLISOLEUCINE; LYSYLLEUCYLGLUTAMINYLASPARTYLALANYLSERYLALANYLGLUTAMYLVALINE; LYSYLTYROSYLTYROSYLPROLYLSERYLSERYLGLUTAMINYLASPARTYLSERINE; PEPTIDE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALGORITHM; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; COMPUTER ANALYSIS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MOLECULAR RECOGNITION; MULTIPLE MYELOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN TARGETING;

EID: 27744434519     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-04-1438     Document Type: Article

References (54)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002;2:927-937.
3. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2004;103:20-32.
4. Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363:875-887.
5. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.
6. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.
7. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113:209-216.
8. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.
9. Kroger N, Shimoni A, Zagrivnaja M, at al. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma. Blood. 2004;104:3361-3363.
10. Yi Q. Immunotherapy in multiple myeloma: current strategies and future prospects. Expert Rev Vaccines. 2003;2:391-398.
11. Costello RT, Fauriat C, Rey J, Gastaut JA, Olive D. Immunobiology of haematological malignant disorders: the basis for novel immunotherapy protocols. Lancet Oncol. 2004;5:47-55.
12. Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood. 1998;91:2459-2466.
13. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma, a feasibility study. Blood. 1999;93:2411-2419.
14. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol. 2000;108:805-816.
15. Wen YJ, Min R, Tricot T, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood. 2002;99:3280-3285.
16. Choi C, Witzens M, Bucur M, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood. 2005;105:2132-2134.
17. Azuma T, Otsuki T, Kuzushima K, Froelich CJ, Fujita S, Yasukawa M. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res. 2004;10:7402-7412.
18. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood. 2002;100:961-965.
19. van Rhee F, Szmania SM, Zhan F, et al. NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105:3939-3944.
20. Wang Z, Zhang Y, Liu H, Salati E, Chiriva-Internati M, Lim SH. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood. 2003;101:955-960.
21. Van Baren N, Brasseur F, Godelaine D, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999;94:1156-1164.
22. Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br J Haematol. 2003;120:3-9.
23. Goto T, Kennel SJ, Abe M, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994;84:1922-1930.
24. Ishikawa J, Kaisho T, Tomizawa H, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics. 1995;26:527-534.
25. Ohtomo T, Sugamata Y, Ozaki Y, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun. 1999;258:583-591.
26. Walter-Yohrling J, Cao X, Callahan M, et al. Identification of genes expressed in malignant cells that promote invasion. Cancer Res. 2003;63:8939-8947.
27. Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther. 2005;4:151-168.
28. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic. 2003;4:694-709.
29. Matsuda A, Suzuki Y, Honda G, et al. Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways. Oncogene. 2003;22:3307-3318.
30. Chiriva-Internati M, Liu Y, Weidanz JA, et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood. 2003;102:3100-3107.
31. Rew SB, Peggs K, Sanjuan I, et al. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin Cancer Res. 2005;11:3377-3384.
32. Hundermer M, Schmit S, Ho A, et al. Identification of T cell epitopes within plasma cell antigen HM1.24 [abstract]. Blood. 2002;100:381b.
33. Tanaka F, Fujie T, Tahara K, et al. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res. 1997;57:4465-4468.
34. Nishioka Y, Nishimura N, Suzuki Y, Sone S. Human monocyte-derived and CD83 (+) blood dendritic cells enhance NK cell-mediated cytotoxicity. Eur J Immunol. 2001;31:2633-2641.
35. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-293.
36. 51Cr-release assay for monitoring cell-mediated cytotoxicity. J Transl Med. 2003;1:14-22.
37. Parker KC, Bednarek MA, Hull LK, et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol. 1992;149:3580-3587.
38. Kondo A, Sidney J, Southwood S, et al. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol. 1995;155:4307-4312.
39. Fruci D, Rovero P, Falasca G, et al. Anchor residue motifs of HLA class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha chains. Hum Immunol. 1993;38:187-192.
40. Tanigaki N, Fruci D, Chersi A, Falasca G, Tosi R, Butler RH. HLA-A2-binding peptides cross-react not only within the A2 subgroup but also with other HLA-A-locus allelic products. Hum Immunol. 1994;39:155-162.
41. Bellantuono I, Gao L, Parry S, et al. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood. 2002;100:3835-3837.
42. Flower DR. Towards in silico prediction of immunogenic epitopes. Trends Immunol. 2003;24:667-674.
43. + cancer patients. Clin Cancer Res. 2004;10:1112-1120.
44. Gross DA, Graff-Dubois S, Opolon P, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004;113:425-433.
45. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100:230-237.
46. Hayashi T, Hideshima T, Akiyama M, et al. Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003;102:1435-1442.
47. Pfeiffer S, Gooding RP, Apperley JF, Goldschmidt H, Samson D. Dendritic cells generated from the blood of patients with multiple myeloma are phenotypically and functionally identical to those similarly produced from healthy donors. Br J Haematol. 1997;98:973-982.
48. Dhodapkar MV, Krasovsky J, Olson K. T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci U S A. 2002;99:13009-13013.
49. pos dendritic precursor cells. Br J Haematol. 2004;124:636-644.
50. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc Natl Acad Sci U S A. 1999;96:5340-5342.
51. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia. 1997;11:1312-1317.
52. Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24. Blood. 1997;90:3179-3186.
53. Ozaki S, Kosaka M, Wakahara Y, et al. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood. 1999;93:3922-3930.
54. Ono K, Ohtomo T, Yoshida K, et al. The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity. Mol Immunol. 1999;36:387-395.